BPC-157

Background

BPC-157 (body protection compound-157) is a synthetic pentadecapeptide originally identified from a protein fraction in human gastric juice and later developed as an experimental “cytoprotective” agent[1][11]. The peptide sequence is commonly reported as GEPPPGKPADDAGLV[1][14]. Interest in BPC-157 stems from a long series of animal studies suggesting effects on wound repair, tendon and ligament healing, gastrointestinal mucosal protection, vascular integrity, and recovery from traumatic or ischemic injury[1][5][11].

Despite extensive preclinical publication, BPC-157 remains an investigational substance. A 2026 review emphasized that no approved formulation exists, no validated dosing regimen has been established, and no completed Phase II clinical trial has been identified[1]. Human evidence is sparse and does not support an approved therapeutic indication in the US or EU[1][6]. The compound is also part of the contemporary “grey market” peptide space and is banned by WADA as an unapproved substance[2][11].

Discovery and origin are usually described within the framework of Robert’s cytoprotection concept, which proposed that gastric-derived factors could protect not only the gastrointestinal mucosa but also other tissues by stabilizing cellular barriers and promoting adaptive perfusion responses[9][11]. BPC-157 is often presented in the literature as a stable gastric peptide that is resistant to degradation in gastric fluid and biologically active across multiple organ systems[1][9][11].

Mechanism of action

The mechanism of BPC-157 is incompletely defined and remains largely inferred from animal and cell studies rather than validated receptor pharmacology in humans[1][11][13]. The literature does not identify a single canonical high-affinity receptor comparable to a conventional peptide hormone receptor. Instead, BPC-157 is described as a pleiotropic modulator of several signaling systems, including nitric oxide (NO), vascular endothelial growth factor (VEGF), Src-Caveolin-1-eNOS signaling, prostaglandin-related pathways, and neurotransmitter systems such as dopamine, serotonin, glutamate, GABA, adrenalin/noradrenalin, and acetylcholine[5][9][12][13].

A recurring mechanistic theme is endothelial and epithelial cytoprotection. Reviews summarize BPC-157 as supporting barrier integrity, opposing “leaky gut” phenomena, and promoting collateral vessel recruitment after vascular compromise[9][12]. In rat pharmacokinetic studies, the peptide was rapidly metabolized after administration, with urinary and biliary excretion and breakdown into smaller fragments and amino acid pathways[14]. This supports a short systemic exposure despite broad biological effects, although the pharmacokinetic–pharmacodynamic relationship remains unresolved[1][14].

In preclinical models, BPC-157 has been reported to normalize disturbed NO signaling, reduce inflammatory injury, promote angiogenesis or vascular remodeling, and accelerate soft-tissue repair[5][7][9][12][13]. These claims are best interpreted as a network-level pharmacology hypothesis rather than a receptor-validated mechanism[1][11][13].

Evidence summary

The evidence base is dominated by preclinical studies. Multiple reviews describe consistent benefit in rat and other animal models involving skin wounds, muscle injury, tendon/ligament lesions, nerve transection, spinal cord injury, bowel injury, ulcer models, ischemia-reperfusion injury, thrombosis, pulmonary hypertension, arrhythmias, and systemic inflammatory or toxicologic challenges[1][5][11][12][13]. However, the strength of this literature is limited by heterogeneous models, sparse replication in independent laboratories, and a lack of robust translational human trials[1][6][11].

The most concrete pharmacokinetic paper in the available set examined rats and dogs and showed that radiolabeled BPC-157 was rapidly absorbed and metabolized, with urine and bile as major excretory routes[14]. This study informs development but does not establish clinical efficacy.

Human data are limited. A recent review states that limited human trials have been reported for knee pain and intravenous safety, but also notes that there has been no completed Phase II clinical trial and no approved dosing regimen[1][6]. The accessible literature in the supplied search results does not provide a definitive, peer-reviewed randomized clinical trial dataset large enough to support efficacy claims for orthopedic healing, inflammatory bowel disease, or neurologic disease[1][6].

Because of this mismatch between animal and human evidence, the current status is best described as early clinical/limited human exposure with strong preclinical interest rather than established clinical utility[1][6][11].

Clinical and research uses

BPC-157 has been studied or discussed for the following investigational uses: tissue repair, musculoskeletal injury recovery, gastrointestinal cytoprotection, inflammatory bowel disease-related models, vascular injury/occlusion, myocardial or pulmonary vascular injury, neural injury, and broader “brain–gut axis” disorders[1][5][7][9][11][12][13].

In the sports-medicine and peptide-therapy literature, it is frequently framed as a potential aid for tendon, ligament, and muscle healing, but the evidence remains preclinical and does not establish a standard-of-care role[2][6][11]. In gastroenterology-oriented literature, it is portrayed as a gastric cytoprotective peptide with theoretical relevance to mucosal injury and leak syndromes[9][11][15].

There is no approved indication in the United States or European Union, and clinical use outside research settings would be off-label and unsupported by regulatory approval[1][11].

Dosing context

No validated clinical dose exists[1]. Animal studies have used a wide range of exposures depending on model and route, including intraperitoneal dosing of 2 or 200 µg/kg in spinal cord injury rats and oral exposure in drinking water in later spinal instability studies[7][10]. The pharmacokinetic paper in rats and dogs indicates rapid metabolism and excretion, which complicates translation of animal schedules to humans[14].

Published human dose-finding data are insufficient to define a therapeutic window[1][6]. The literature therefore provides only reported research exposures, not a clinical regimen. Routes discussed in the literature include oral, intraperitoneal, topical/local, and injectable approaches; however, none has an approved label, validated bioequivalence standard, or established duration of effect in humans[1][14].

Safety profile

The overall safety signal in the preclinical literature is often described as favorable, but this impression is limited by the lack of large controlled human studies and by the possibility of publication bias[1][11]. A recent review notes that only a few side effects have been reported following administration, but also emphasizes the absence of comprehensive randomized clinical safety data[11].

Known or suspected risks include the general uncertainties of unapproved peptide products: contamination, variable potency, route-dependent administration risks, and lack of standardized formulation quality[1][11]. Because BPC-157 is not approved, contraindications are not formally established. Practical cautions in the literature include avoidance in pregnancy and lactation due to absent data, caution in patients with active malignancy or pro-angiogenic concerns given theoretical VEGF-related effects, and caution in individuals requiring evidence-based anticoagulation or cardiovascular management because vascular effects are described but not clinically validated[9][12][13].

No robust human toxicity thresholds, reproductive toxicology package, or long-term carcinogenicity dataset is available in the provided sources[1][11][14].

Regulatory status

BPC-157 is not approved as a medicinal product in the United States or the European Union[1][11]. The 2026 review found no approved formulation and no completed Phase II clinical trial, indicating that the compound remains in the investigational or preclinical-development category[1]. It is also listed by WADA among prohibited unapproved substances[2][11].

For encyclopedia purposes, the appropriate regulatory description is: investigational peptide with extensive preclinical literature, limited human data, no approved therapeutic indication, and no established clinical dosing standard[1][6][11].